Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, MAY 14, 2026 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY ANNOUNCED THAT ANGELOS STERGIOU, MD, SCD H.C., PRESIDENT AND CHIEF EXECUTIVE OFFICER OF SELLAS, WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: 2026 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM FORMAT: CORPORATE PRESENTATION AND FIRESIDE CHAT DATE AND TIME: TUESDAY, MAY 19, 2026, AT 2:00 PM ET LOCATION: NEW YORK, NY WEBCAST LINK: CLICK HERE A.G.P.

SELLAS LIFE SCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

 CONTRACT RESEARCH ORGANIZATION FOR THE PIVOTAL PHASE 3 REGAL TRIAL OF GALINPEPIMUT-S (GPS) IN ACUTE MYELOID LEUKEMIA (AML) INFORMED THE COMPANY THAT 78 EVENTS HAVE OCCURRED IN THE TRIAL AS OF MAY 11, 2026; SELLAS REMAINS BLINDED TO TRIAL OUTCOMES   FINAL ANALYSIS OF REGAL TRIAL OF GPS IN AML TO BE CONDUCTED FOLLOWING THE 80 TH EVENT   ONGOING DOSING OF PATIENTS IN PHASE 2 TRIAL OF SLS009 IN NEWLY DIAGNOSED FIRST LINE AML   $107.1 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2026; ADDITIONAL $7.5 MILLION IN PROCEEDS RECEIVED IN Q2 2026 TO DATE THROUGH WARRANT EXERCISES  NEW YORK, MAY 12, 2026 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS'' OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE. THE FIRST QUARTER OF 2026 MARKED AN IMPORTANT PERIOD FOR SELLAS AS WE CONTINUED TO EXECUTE ACROSS OUR CLINICAL PROGRAMS WHILE PREPARING FOR THE ANTICIPATED PIVOTAL PHASE 3 REGAL TRIAL DATA READOUT, SAID ANGELOS STERGIOU, MD, SCD H.C.

SELLAS LIFE SCIENCES REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

 CONTINUED ADVANCEMENT OF PIVOTAL PHASE 3 REGAL TRIAL OF GALINPEPIMUT-S (GPS) IN ACUTE MYELOID LEUKEMIA (AML) - FINAL ANALYSIS UPON REACHING 80 EVENTS 

SELLAS LIFE SCIENCES REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

- PRECLINICAL DATA SHOW THAT SLS009 LOWERS THE APOPTOTIC THRESHOLD IN AML CELLS BY SUPPRESSING CRITICAL SURVIVAL PATHWAYS - - PRECLINICAL DATA SHOW THAT SLS009 LOWERS THE APOPTOTIC THRESHOLD IN AML CELLS BY SUPPRESSING CRITICAL SURVIVAL PATHWAYS -

SELLAS LIFE SCIENCES TO PRESENT PRECLINICAL DATA HIGHLIGHTING POTENT ACTIVITY OF SLS009 IN AML AT THE 2026 AACR CONFERENCE

- STUDY TO ENROLL 80 PATIENTS UNLIKELY TO BENEFIT FROM VENETOCLAX/AZACITIDE (AZA/VEN) THERAPY IN THE US AND EUROPE - - SELLAS' PREDICTIVE BIOMARKER AND AI ASSISTED PRECISION MEDICINE MODELS TO BE UTILIZED - - TOPLINE DATA EXPECTED IN Q4 2026 

SELLAS LIFE SCIENCES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN NEWLY DIAGNOSED FIRST-LINE AML TRIAL OF SLS009

NEW YORK, JAN. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS'' OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT WITH IMPACT-AML, A EUROPEAN COLLABORATIVE INITIATIVE DEDICATED TO ADVANCING INNOVATIVE TREATMENTS FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML). UNDER THE AGREEMENT, THE IMPACT-AML NETWORK WILL CONDUCT A CLINICAL STUDY EVALUATING SLS009, A HIGHLY SELECTIVE CDK9 INHIBITOR, ENABLING ACCESS TO MULTIPLE EUROPEAN CLINICAL SITES AND PATIENTS.

SELLAS LIFE SCIENCES ENTERS AGREEMENT WITH IMPACT-AML TO EXPAND SLS009 CLINICAL PROGRAM INTO EUROPE

NEW YORK, DEC. 29, 2025 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS'' OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY PROVIDED AN UPDATE ON THE ONGOING PHASE 3 REGAL TRIAL EVALUATING GPS AS A POTENTIAL MAINTENANCE THERAPY IN PATIENTS WITH AML AFTER SECOND COMPLETE REMISSION (CR2).

SELLAS LIFE SCIENCES PROVIDES UPDATE ON PIVOTAL PHASE 3 REGAL TRIAL OF GALINPEPIMUT-S (GPS) IN ACUTE MYELOID LEUKEMIA (AML)

NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS'' OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY ANNOUNCED THAT CLINICAL DATA FROM ITS ONGOING PHASE 2 STUDY OF SLS009, A HIGHLY SELECTIVE CDK9 INHIBITOR, IN COMBINATION WITH AZACITIDINE (AZA) AND VENETOCLAX (VEN) FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) WITH MYELODYSPLASTIC SYNDROME-RELATED CHANGES (AML-MR) AFTER PRIOR VEN-BASED TREATMENT WERE PRESENTED TODAY AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION, BEING HELD DECEMBER 6  9, 2025, IN ORLANDO, FLORIDA.

SELLAS LIFE SCIENCES PRESENTS POSITIVE PHASE 2 DATA OF SLS009 IN COMBINATION WITH AZA/VEN IN RELAPSED/REFRACTORY AML-MR AT ASH 2025

NEW YORK, OCT. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY ANNOUNCED THE IMMEDIATE EXERCISE OF WARRANTS, PREVIOUSLY ISSUED IN MARCH AND AUGUST 2024 (THE EXISTING WARRANTS), TO PURCHASE UP TO 22,363,714 SHARES OF ITS COMMON STOCK FOR GROSS CASH PROCEEDS OF APPROXIMATELY $31.0 MILLION.

SELLAS LIFE SCIENCES GROUP ANNOUNCES EXERCISE OF EXISTING WARRANTS HELD BY A CURRENT INSTITUTIONAL INVESTOR FOR $31 MILLION IN GROSS PROCEEDS

-    FINAL ANALYSIS ANTICIPATED BY YEAR-END UPON OCCURRENCE OF 80 EVENTS  - NEW YORK, AUG. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS'' OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY ANNOUNCED THAT THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC) HAS COMPLETED A PRE-SPECIFIED ANALYSIS OF THE PHASE 3 REGAL TRIAL OF GALINPEPIMUT-S (GPS) IN ACUTE MYELOID LEUKEMIA (AML), AND HAS ISSUED A POSITIVE RECOMMENDATION TO CONTINUE THE TRIAL WITHOUT MODIFICATION. THE IDMC CONCLUDED THAT THE RISK-BENEFIT PROFILE OF GPS SUPPORTS CONTINUED EVALUATION UNDER THE CURRENT STUDY PROTOCOL.

SELLAS LIFE SCIENCES ANNOUNCES INDEPENDENT DATA MONITORING COMMITTEE PERIODIC REVIEW AND POSITIVE RECOMMENDATION TO CONTINUE PIVOTAL PHASE 3 REGAL TRIAL OF GPS IN AML WITHOUT MODIFICATION

SELLAS Life Sciences Group, Inc.

SLS

Price

Financial Reports

No items found.

Press Releases

SELLAS Life Sciences Group, Inc.

SLS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SLS